Firefly Neuroscience, Inc. (AIFF) jumped more than 48% after the company announced a breakthrough discovery of new brain-wave biomarkers that may help distinguish between the three major subtypes of ADHD.
The findings come from Firefly's FDA-cleared Evoke EEG/ERP platform, which uses AI to analyze brain-signal patterns. According to the company, the newly identified biomarkers could offer clinicians an objective way to differentiate between hyperactive-impulsive, inattentive, and combined-type ADHD- a process that today relies almost entirely on symptom checklists and subjective assessments.
Firefly says the discovery could eventually support more precise treatment decisions, guide medication selection, and help monitor whether a therapy is working. The research also advances the company's broader goal of building a large-scale EEG/ERP "brain functional model" trained on more than 191,000 brain scans.
AIFF has traded between $0.62 and $6.00 over the past year. The stock is currently trading at $2.58, up 48.28%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.